Pharmacyclics (PCYC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JMarcus who wrote (694)	1/16/2004 3:45:53 PM
From: Icebrg	Read Replies (1) of 717

Marc >>It just so happens that NSCLC metastasizing to the brain provides a unique opportunity to show demonstrable therapeutic benefits without extending the trial all the way out to the traditional endpoint of a survival benefit. Which isn't to say that the drug has no survival benefit. Quite the contrary. The endpoint of neurological progression is just faster and easier to prove.>> If the drug works as expected this will no doubt be a relatively "fast and easy" way to approval. The reason traditional endpoints like survival or time to disease progression can not be used is that these patients, who are suffering from a systemic disease, may well die from other manifestations of the disease. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next